Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Li Huo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1216-083X; OpenAlex author ID A5032681207. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 0, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 trial · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 7

  1. Feasibility of simplified Patlak parametric imaging with scaled population-based input function on pancreatic cancer. Last author DOI 10.1186/s40658-025-00758-z↗
  2. Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological c… Co-author DOI 10.1007/s00259-022-06100-4↗
  3. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the… Last author DOI 10.1007/s00259-023-06297-y↗
  4. Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on 18F-FDG PET/CT radiomics. Last author DOI 10.1186/s13550-021-00760-3↗
  5. SPECT Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts in Vivo Co-author DOI 10.21203/rs.3.rs-142194/v1↗
  6. Scintigraphic Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts In V… Co-author DOI 10.3389/fonc.2021.792431↗
  7. Focal Autoimmune Pancreatitis Mimicking Pancreatic Cancer on FDG PET/CT Imaging. Last author DOI 10.1097/rlu.0000000000001901↗

Trials 1

  1. 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma Principal investigator NCT05275985↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhixin Hao · 4 shared papers, 2021–2025 · strength 0.71
  2. Jiangdong Qiu · 3 shared papers, 2023–2025 · strength 0.57
  3. Taiping Zhang · 3 shared papers, 2023–2025 · strength 0.57
  4. Jie Ding · 3 shared papers, 2021–2023 · strength 0.47
  5. Wenming Wu · 2 shared papers, 2023–2025 · strength 0.40
  6. Qiaofei Liu · 2 shared papers, 2023 · strength 0.33
  7. Xiang Li · 2 shared papers, 2023 · strength 0.33
  8. Hua Huang · 2 shared papers, 2023 · strength 0.33
  9. Xiaona Jin · 2 shared papers, 2021 · strength 0.28
  10. Fan Wang · 2 shared papers, 2021 · strength 0.28
  11. Haiqun Xing · 2 shared papers, 2018–2021 · strength 0.26
  12. Wenming Wu · 1 shared paper, 2023 · strength 0.17
  13. Fang Li · 1 shared paper, 2021 · strength 0.14
  14. Fang Li · 1 shared paper, 2021 · strength 0.14
  15. Lichun Zheng · 1 shared paper, 2018 · strength 0.12
  16. Fang Li · 1 shared paper, 2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.